1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
DeSantis CE, Lin CC, Mariotto AB, et al:
Cancer treatment and survivorship statistics, 2014. CA Cancer J
Clin. 64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Funk GF, Karnell LH, Robinson RA, Zhen WK,
Trask DK and Hoffman HT: Presentation, treatment, and outcome of
oral cavity cancer: a National Cancer Data Base report. Head Neck.
24:165–180. 2002. View Article : Google Scholar : PubMed/NCBI
|
4
|
Alsaleh G and Gottenberg JE:
Characterization of microRNAs and their targets. Methods Mol Biol.
1142:55–63. 2014.PubMed/NCBI
|
5
|
Di Leva G and Croce CM: miRNA profiling of
cancer. Curr Opin Genet Dev. 23:3–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Bajan S and Hutvagner G: Regulation of
miRNA Processing and miRNA Mediated Gene Repression in Cancer.
Microrna. 3:10–17. 2014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Wu BH, Xiong XP, Jia J and Zhang WF:
MicroRNAs: new actors in the oral cancer scene. Oral Oncol.
47:314–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
Wang RT, Xu M, Song ZG, Xu CX and Jin H:
Decreased Expression of miR-216a Contributes to Non-small Cell Lung
Cancer Progression. Clin Cancer Res. 20:4705–4716. 2014. View Article : Google Scholar : PubMed/NCBI
|
9
|
Xia H, Ooi LL and Hui KM:
MicroRNA-216a/217-induced epithelial-mesenchymal transition targets
PTEN and SMAD7 to promote drug resistance and recurrence of liver
cancer. Hepatology. 58:629–641. 2013. View Article : Google Scholar : PubMed/NCBI
|
10
|
Hou B, Jian Z, Chen S, Ou Y, Li S and Ou
J: Expression of miR-216a in pancreatic cancer and its clinical
significance. Nan Fang Yi Ke Da Xue Xue Bao. 32:1628–1631. 2012.In
Chinese. PubMed/NCBI
|
11
|
Jia AY, Castillo-Martin M, Bonal DM,
Sánchez-Carbayo M, Silva JM and Cordon-Cardo C: MicroRNA-126
inhibits invasion in bladder cancer via regulation of ADAM9. Br J
Cancer. 110:2945–2954. 2014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Zhang Z, Kim K, Li X, et al: MicroRNA-26b
Represses Colon Cancer Cell Proliferation by Inhibiting Lymphoid
Enhancer Factor 1 Expression. Mol Cancer Ther. 13:1942–1951. 2014.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Song Q, Xu Y, Yang C, et al: miR-483-5p
promotes invasion and metastasis of lung adenocarcinoma by
targeting RhoGDI1 and ALCAM. Cancer Res. 74:3031–3042. 2014.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Pan W, Wang H, Jianwei R and Ye Z:
MicroRNA-27a promotes proliferation, migration and invasion by
targeting MAP2K4 in human osteosarcoma cells. Cell Physiol Biochem.
33:402–412. 2014. View Article : Google Scholar : PubMed/NCBI
|
15
|
Chen PJ, Yeh SH, Liu WH, et al: Androgen
pathway stimulates microRNA-216a transcription to suppress the
tumor suppressor in lung cancer-1 gene in early
hepatocarcinogenesis. Hepatology. 56:632–643. 2012. View Article : Google Scholar : PubMed/NCBI
|
16
|
Benne R and Hershey JW: The mechanism of
action of protein synthesis initiation factors from rabbit
reticulocytes. J Biol Chem. 253:3078–3087. 1978.PubMed/NCBI
|
17
|
Schreier MH, Erni B and Staehelin T:
Initiation of mammalian protein synthesis. I Purification and
characterization of seven initiation factors. J Mol Biol.
116:727–753. 1977. View Article : Google Scholar : PubMed/NCBI
|
18
|
Horvilleur E, Sbarrato T, Hill K, et al: A
role for eukaryotic initiation factor 4B overexpression in the
pathogenesis of diffuse large B-cell lymphoma. Leukemia.
28:1092–1102. 2014. View Article : Google Scholar :
|
19
|
Ren K, Gou X, Xiao M, et al: The
over-expression of Pim-2 promote the tumorigenesis of prostatic
carcinoma through phosphorylating eIF4B. Prostate. 73:1462–1469.
2013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Yang J, Wang J, Chen K, et al: eIF4B
phosphorylation by pim kinases plays a critical role in cellular
transformation by Abl oncogenes. Cancer Res. 73:4898–4908. 2013.
View Article : Google Scholar : PubMed/NCBI
|